Safety and efficacy of anti-IL-5 monoclonal antibodies as second-line therapy for chronic rhinosinusitis with nasal polyps: a meta-analysis - PubMed
4 hours ago
- #meta-analysis
- #chronic rhinosinusitis
- #anti-IL-5 antibodies
- Anti-IL-5 monoclonal antibodies (anti-IL-5 mAb) were evaluated as second-line therapy for chronic rhinosinusitis with nasal polyps (CRSwNP) in a meta-analysis.
- The analysis included 10 randomized controlled trials comparing anti-IL-5 mAb to placebo, showing significant improvements in key outcomes such as nasal polyp score and SNOT-22 score.
- Secondary outcomes like nasal blockage, loss of smell, and Lund-Mackay scores also improved significantly with anti-IL-5 mAb therapy.
- Anti-IL-5 mAb reduced the need for first-time nasal polyp surgeries and systemic corticosteroid courses compared to placebo.
- The therapy was found to be safe and effective, supporting its use as a second-line treatment option for CRSwNP.